Home

GeneCentric: The Next Generation of Cancer Diagnosis and Treatment

GeneCentric is leading the industry in the advanced classification of cancers for more effective drug development and more accurate diagnosis and treatment of patients. Cancer Subtype Platform (CSP™), our proprietary core technology, identifies biologic subtypes through an integrated analysis of tumor genomics, leading to rational clinical trial design, accurate prediction of drug response, more efficient target selection in drug development and improved treatment outcomes.

CSP™ is driving our promising pipeline of oncology diagnostics, with an initial focus on lung cancer and head and neck cancer. CSP™ has demonstrated clinical utility and has significant potential for drug development, drug repurposing and life cycle management. Our first product, which was developed using CSP™ and is available as HistoPlusSM: Lung Cancer, was launched with our partner LabCorp®.

With our game-changing technology platform, robust pipeline, experienced leadership team, and business model that enables the rapid development of genomic tumor classifers, GeneCentric is revolutionizing cancer treatment.

CLINICAL PRODUCTS & PIPELINE
LUNG CANCER HEAD & NECK PUBLICATIONS
PARTNERSHIP & COLLABORATION

A GeneCentric® Strategic Collaboration (GSC) integrates the unique strengths of GeneCentric with its partner’s capabilities to more rapidly and efficiently advance the development and adoption of novel cancer diagnostics in the clinic.

RECENT POSTS